Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Hikma trims full year revenue forecast on Advair U.S. launch delay

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/19/2017 | 09:32am CEST

Drugmaker Hikma Pharmaceuticals Plc on Friday lowered its revenue forecast for the full year to reflect a delay in the launch of its generic asthma drug, after U.S. regulators denied approval citing "major" issues with the application.

Shares of the company fell as much 7.47 percent to 1,573 pence, the lowest since May, 2014. They were the top loser on the FTSE 100 bluechip index and the pan-European Stoxx 600 index.

Hikma now expects full-year revenue to be in the range of $2.0 billion-$2.1 billion at constant currency, down from its earlier forecast of $2.2 billion (1.7 billion pounds).

Earlier this month, the company said approval for its generic version of GlaxoSmithKline Plc's blockbuster lung drug Advair was unlikely in 2017.

Hikma and its partner Vectura Group Plc are in a race with Mylan to launch the first U.S. generic copy of Advair. The FDA has already delayed approval of Mylan's version.

Hikma on Friday lowered its 2017 revenue forecast for its generics business to $670 million, down from its earlier forecast of $800 million.

"This assumes we do not launch our generic version of Advair Diskus in 2017 and reflects the intensifying competitive environment in the U.S.," the company said in a statement.

Hikma maintained its full-year revenue estimate for its injectables unit at a range of $800 million-$825 million, with core operating margin seen in the high 30s.

(Reporting by Sanjeeban Sarkar and Tenzin Pema in Bengaluru; Editing by Sunil Nair)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE
07/24 GLAXOSMITHKLINE : GSK submits US regulatory filing of Arnuity Ellipta in childre..
07/24 BIOTECH MOVERS AT BOTH END OF THE SP : GlaxoSmithKline plc (ADR) (NYSE:GSK) And ..
07/24 GLAXOSMITHKLINE : LATTE-2 phII results presented at IAS in Paris
07/21DJGLAXOSMITHKLINE : FDA Approves Injectable Form Of Glaxo's Benlysta
07/21GLAXOSMITHKLINE PLC : half-yearly earnings release
07/21 GLAXOSMITHKLINE : GSK receives FDA approval for a new self-injectable formulatio..
07/21 GlaxoSmithKline's new CEO prepares to trim drug pipeline
07/21 GLAXOSMITHKLINE : GSK Submits EU Filing for Extended Use of Relvar Ellipta in Pa..
07/21 GLAXOSMITHKLINE : GSK announces Board and Committee changes
07/20 GLAXOSMITHKLINE : Reports from GlaxoSmithKline plc Advance Knowledge in Asthma (..
More news
News from SeekingAlpha
07/24 Glaxo submits U.S. marketing application for expanded use of asthma med Arnui..
07/24 3 THINGS IN BIOTECH YOU SHOULD LEARN : July 24, 2017
07/23 Tracking Ken Fisher'S Fisher Asset Management Portfolio - Q2 2017 Update
07/21 FDA OKs self-injectable formulation of Glaxo's SLE med Benlysta
07/21 Glaxo submits marketing application in Europe for extended use of Relvar Elli..
Financials ( GBP)
Sales 2017 30 086 M
EBIT 2017 8 318 M
Net income 2017 4 356 M
Debt 2017 13 962 M
Yield 2017 5,01%
P/E ratio 2017 17,91
P/E ratio 2018 15,70
EV / Sales 2017 3,07x
EV / Sales 2018 2,95x
Capitalization 78 473 M
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 17,8  GBP
Spread / Average Target 12%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Patrick J. T. Vallance Executive Director, President-R&D
Roy Malcolm Anderson Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE2.14%102 231
JOHNSON & JOHNSON15.45%358 307
ROCHE HOLDING LTD.4.90%221 333
NOVARTIS8.37%220 169
PFIZER2.59%198 425
MERCK AND COMPANY6.29%171 139